Fenbendazole and Ivermectin in Pancreatic Cancer: Pattern Analysis of Anecdotal Case Reports (2026)

Abstract

Background

Pancreatic cancer remains one of the most lethal malignancies despite modern chemotherapy. Increasing public interest has emerged around repurposed antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin.

Objective

To reorganise and analyse anecdotal pancreatic cancer case reports involving fenbendazole and ivermectin-based protocols in order to identify recurring response patterns and clinically relevant subgroups.

Methods

Publicly available anecdotal reports were reviewed qualitatively and reorganised according to biomarker response, metastatic pattern, chemotherapy use, histology, and adjunct metabolic therapies.

Results

Recurring themes included rapid CA19-9 decline, apparent liver metastasis responses, heavy reliance on combination chemotherapy, delayed-response patterns, and extensive use of nutraceutical adjuncts. Most reported responders received multi-modal therapy rather than antiparasitic monotherapy.

Conclusion

The reports are highly vulnerable to selection bias, publication bias, survivorship bias, and treatment confounding. However, the recurring signals may justify prospective registries and mechanistic studies.

Keywords: pancreatic cancer, fenbendazole, ivermectin, repurposed drugs, integrative oncology, CA19-9, liver metastases

Introduction

Pancreatic cancer is among the most aggressive and difficult cancers to treat, particularly in its later stages. Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. 

Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is a cancer which is difficult to effectively treat as it is often detected late in the disease process. Almost all PDACs (over 90%) have activating mutations in the GTPase gene KRAS.

Pancreatic cancer has a high mortality rate and is often resistant to conventional treatments. Standard therapeutic options include surgical resection, chemotherapy, radiation therapy, and targeted therapy for pancreatic cancer with actionable mutations; yet survival rates remain low due to resistance. 

Standard treatments such as FOLFIRINOX and gemcitabine-based regimens improve survival modestly, but durable remission remains uncommon in metastatic disease.

Recently, integrative treatment strategies have gained interest, including the repurposing of existing drugs originally developed for non-cancer indications. Repurposed antiparasitic agents including fenbendazole, mebendazole, and ivermectin have gained attention in integrative oncology communities. Proposed mechanisms from preclinical studies include:

• Microtubule disruption;

• Autophagy modulation;

• Metabolic interference;

• Chemotherapy sensitisation;

• Immunomodulation.

Metastatic pancreatic adenocarcinoma remains one of the deadliest cancers, with median survival historically reported at approximately 3–6 months in advanced untreated disease (PubMed 2024), and roughly 11–12 months even with modern chemotherapy in many studies. Against this background, multiple anecdotal case reports involving fenbendazole and ivermectin protocols have described survival beyond 1 year, including cases reporting tumor regression, CA19-9 decline, and prolonged disease stabilisation.

However, the existing evidence is largely anecdotal and poorly organised. This review restructures publicly available reports into clinically meaningful subgroups to identify recurring themes.

---

Materials and Methods

Source Material

Cases were derived from a publicly accessible online compilation of pancreatic cancer anecdotal reports involving fenbendazole-based protocols.

Study Design

This review represents a qualitative hypothesis-generating analysis. No independent verification of patient outcomes was performed.

Analytical Categories

Cases were reorganised according to:

1. Biomarker response;

2. Metastatic response pattern;

3. Combination chemotherapy use;

4. Treatment-refractory disease;

5. Histologic subtype;

6. Adjunct metabolic therapies;

7. Response kinetics.

---

Results

1. Rapid CA19-9 Responder Subgroup

One of the most consistent observations was rapid decline in CA19-9 levels.

Common Features

• High baseline tumor burden;

• Elevated CA19-9;

• Concurrent radiologic response;

• Frequent liver metastases;

• Combination therapy use.

Several reports described major CA19-9 reductions within weeks to months, often accompanied by reduction in pancreatic and hepatic lesions.

Interpretation

Possible explanations include:

• Enhanced chemotherapy sensitivity;

• Genuine biologic activity;

• Selection bias toward exceptional responders.

Complete response — NED / Cancer Free / Remission (14 cases)

Explicitly confirmed no evidence of disease by CT, PET/CT, or molecular testing (SIGNATERA), or oncologist-confirmed remission — the highest response tier in a cancer where median survival is 3–6 months.

#1 · Anon, USA#2 · Anon, USA#3 · Anon, USA#4 · Anon, USA#17 · 67F, USA#18 · 36F, USA#20 · Anon, Canada#24 · 53M, USA#28 · 67M, USA#30 · 69F, Korea/FL#32 · 66M, Netherlands#35 · 43F, Canada/Arg#38 · 77F, Canada#41 · 70M, NZ

Dramatic response — >70% tumor shrinkage or >90% CA19-9 drop (12 cases)

Major radiologic and/or biomarker responses far exceeding expectations for chemotherapy alone. Several oncologists commented they had never seen results like these in decades of practice. Case 19 achieved 99.7% volume reduction of a liver metastasis over 4 months.

#7 · 40s M, USA#9 · 77M, USA#14 · 63F, Philippines#16 · 78M, USA (NET)#19 · 66M, Netherlands#21 · 57M, USA#23 · 69M, USA#33 · 54M, France#34 · 68F, USA#39 · 75M, Romania#40 · 56M, Canada#44 · 77M, USA

---

2. Liver Metastasis Response Subgroup

A striking recurring theme involved apparent shrinkage of liver metastases.

Clinical Significance

Liver metastases are generally associated with:

• Poor prognosis;

• Chemotherapy resistance;

• Rapid progression.

Despite this, multiple anecdotal reports described substantial hepatic regression.

Observed Patterns

• Reduction in liver lesion size;

• Near-complete radiologic responses;

• Stabilisation after prior progression.

Potential Explanations

• Altered hepatic drug metabolism;

• Tumor microenvironment effects;

• Delayed chemotherapy response;

• Reporting bias.

---

3. Combination Therapy Subgroup

Most apparent responders did not receive antiparasitic monotherapy.

Common Co-Interventions

• FOLFIRINOX;

• Gemcitabine-based chemotherapy;

• NALIRIFOX;

• Radiation;

• Surgery.

Interpretation

The reports may be more accurately interpreted as integrative oncology protocols rather than isolated fenbendazole therapy.

Potential mechanisms include:

• Chemotherapy sensitisation;

• Multidrug resistance modulation;

• Metabolic stress enhancement.

---

4. Chemotherapy-Refractory Disease Subgroup

Several anecdotal cases reportedly progressed despite conventional treatment before later stabilisation or regression.

Common Characteristics

• Prior FOLFIRINOX failure;

• Post-surgical recurrence;

• Metastatic progression.

Interpretation

These reports generate hypotheses regarding possible reversal of treatment resistance, although causality cannot be established.

Chemo-refractory — documented tumor growth on active chemo before adding repurposed drugs5 cases

Markers rising and/or tumor growing on 1–4 lines of chemotherapy when IVM/FBZ/MBZ was introduced. The contrast between chemo failure and subsequent response highlights the drugs' potential as rescue agents.

#6 · Anon F, USA#7 · 40s M, USA#15 · 66M, USA#17 · 67F, USA#26 · 71M, USA

---

5. Drug Regimen

High-Dose Antiparasitic Protocol Subgroup

Multiple cases used substantially higher doses than commonly discussed online.

Reported Dosing Patterns

Fenbendazole

• 888 mg/day;

• 1000–2000 mg/day.

Ivermectin

• Approximately 1.0–1.5 mg/kg/day.

Concerns

• Limited toxicity reporting;

• Unknown long-term safety;

• Potential hepatic toxicity;

• Drug-drug interaction uncertainty.

IVM + FBZ21 cases

The dominant regimen across the series — ivermectin and fenbendazole together. Typically used alongside conventional chemotherapy as a dual chemosensitizer.

#1 · Anon, USA#2 · Anon, USA#5 · 50s M, USA#6 · Anon F, USA#7 · 40s M, USA#10 · 53M, USA#11 · 46M, USA#12 · 57M, USA#13 · 46M, USA#14 · 63F, Philippines#19 · 66M, Netherlands#20 · Anon, Canada#22 · 57M, S Korea#24 · 53M, USA#25 · 68M, Jordan#26 · 71M, USA#29 · 60M, USA#34 · 68F, USA#37 · 71F, Slovakia#40 · 56M, Canada#43 · 65M, USA

IVM + FBZ + CBD oil / HBOT / other adjuncts8 cases

IVM and FBZ augmented with CBD oil (most common adjunct), hyperbaric oxygen therapy (HBOT), or modified citrus pectin — suggesting cumulative benefit from additional agents.

#16 · 78M, USA (NET)#17 · 67F, USA#21 · 57M, USA#23 · 69M, USA#30 · 69F, Korea/FL#31 · 62M, USA#32 · 66M, Netherlands#41 · 70M, NZ

IVM + MBZ (mebendazole, no fenbendazole)6 cases

Ivermectin paired with mebendazole — the FDA-approved human-use benzimidazole. Often prescribed when fenbendazole was unavailable or as a deliberate regimen choice.

#8 · Anon, USA#15 · 66M, USA#28 · 67M, USA#33 · 54M, France#36 · 38F, USA#42 · Anon M, USA

Triple: IVM + FBZ + MBZ3 cases

All three antiparasitic agents combined for maximum benzimidazole coverage. Notable: all three cases achieved strong or complete responses.

#35 · 43F, Canada/Arg#38 · 77F, Canada#39 · 75M, Romania

FBZ + MBZ (no ivermectin)2 cases

Dual benzimidazole therapy without ivermectin. Case 44 also incorporated metabolic repurposed drugs (metformin, lovastatin, berberine), producing a 99.95% CA19-9 drop.

#9 · 77M, USA#44 · 77M, USA

Single-agent or predominantly single-drug cases4 cases

Mostly early reports (Cases 1–3) using fenbendazole primarily; Cases 4 and 27 used mebendazole alone; Case 18 used ivermectin alone for 3 months before chemo/radiation. All achieved complete responses.

#3 · Anon, USA#4 · Anon, USA#18 · 36F, USA#27 · 67F, USA

Combined with active chemotherapy (as chemosensitizer)

31 cases

The most common pattern — antiparasitics added alongside ongoing chemo (FOLFIRINOX, NALIRIFOX, Gemcitabine/Abraxane, etc.). Multiple cases show only modest chemo response before IVM/FBZ was added, then dramatic improvement — a compelling before/after contrast seen most clearly in Case 33.

#1 · Anon, USA#2 · Anon, USA#3 · Anon, USA#5 · 50s M, USA#7 · 40s M, USA#8 · Anon, USA#10 · 53M, USA#11 · 46M, USA#12 · 57M, USA#13 · 46M, USA#14 · 63F, Philippines#18 · 36F, USA#19 · 66M, Netherlands#20 · Anon, Canada#22 · 57M, S Korea#24 · 53M, USA#27 · 67F, USA#28 · 67M, USA#29 · 60M, USA#30 · 69F, Korea/FL#31 · 62M, USA#32 · 66M, Netherlands#33 · 54M, France#34 · 68F, USA#36 · 38F, USA#37 · 71F, Slovakia#39 · 75M, Romania#40 · 56M, Canada#42 · Anon M, USA#43 · 65M, USA#44 · 77M, USA

Added after documented chemo failure (chemo-refractory)4 cases

Tumors were actively progressing on chemotherapy when repurposed drugs were started — and all four cases responded. Case 17 is the starkest: 3 months of FOLFIRINOX with no benefit, then NED within 2.5 months of IVM+FBZ.

#6 · Anon F, USA#15 · 66M, USA#17 · 67F, USA#26 · 71M, USA

No chemotherapy — repurposed drugs only9 cases

Patients who received no concurrent or sequential chemotherapy at all. Three achieved NED (Cases 4, 35, 41), two showed dramatic responses >70% (Cases 9, 21), suggesting a direct tumor-suppressing effect independent of chemo.

#4 · Anon, USA#9 · 77M, USA#16 · 78M, USA (NET)#21 · 57M, USA#23 · 69M, USA#25 · 68M, Jordan#35 · 43F, Canada/Arg#38 · 77F, Canada#41 · 70M, NZ

---

6. Neuroendocrine Tumor Subgroup

The article combined biologically distinct pancreatic cancers.

Importance

Pancreatic neuroendocrine tumors differ from PDAC in:

• Growth kinetics;

• Molecular biology;

• Prognosis;

• Therapeutic responsiveness.

Several neuroendocrine cases reportedly demonstrated major radiologic regression, suggesting that future analyses should separate these tumors from PDAC.

---

7. Metabolic and Nutraceutical Adjunct Subgroup

Many patients used extensive metabolic protocols alongside antiparasitic therapy.

Frequently Reported Adjuncts

• Curcumin;

• CBD oil;

• Quercetin;

• Berberine;

• Vitamin D;

• Turkey tail mushroom;

• Omega-3 fatty acids;

• Dietary carbohydrate restriction.

Interpretation

These regimens represent complex multi-intervention protocols, making attribution difficult.

IVM + FBZ + CBD oil / HBOT / other adjuncts8 cases

IVM and FBZ augmented with CBD oil (most common adjunct), hyperbaric oxygen therapy (HBOT), or modified citrus pectin — suggesting cumulative benefit from additional agents.

#16 · 78M, USA (NET)#17 · 67F, USA#21 · 57M, USA#23 · 69M, USA#30 · 69F, Korea/FL#31 · 62M, USA#32 · 66M, Netherlands#41 · 70M, NZ

Cross-Case Patterns

Pattern 1: Liver Metastases Frequently Responded

This was one of the strongest recurring observations.

Pattern 2: Delayed Responses Occurred

Several reports described apparent progression before later improvement.

Pattern 3: Multi-Modal Therapy Dominated

Most patients used chemotherapy, supplements, dietary intervention, and multiple repurposed drugs simultaneously.

Pattern 4: Emotional Narrative Framing

Many cases used highly emotional language, increasing susceptibility to publication and survivorship bias.

---

Discussion

The strongest apparent signals from the anecdotal reports include:

• Rapid CA19-9 decline;

• Liver metastasis responses;

• Possible chemotherapy synergy;

• Delayed-response kinetics;

• Potential neuroendocrine responsiveness.

However, major methodological limitations severely restrict interpretation.

Key Limitations

Lack of Independent Verification

Most reports relied on self-reporting and unverified imaging interpretations.

Treatment Confounding

Concurrent chemotherapy prevents isolation of independent drug effects.

Selection Bias

Exceptional responders are more likely to be publicly reported than non-responders.

Missing Clinical Data

Frequently absent data included:

• RECIST measurements;

• Overall survival;

• Molecular profiling;

• Toxicity grading;

• KRAS and BRCA status.

Heterogeneous Disease Biology

Different tumor subtypes and treatment strategies were combined in the same dataset.

---

Future Research Directions

Potential future research areas include:

Prospective Registries

Standardised collection of imaging, biomarkers, dosing, toxicity, and survival data.

Biomarker-Stratified Studies

Evaluation by:

• KRAS subtype;

• BRCA mutation;

• Histology;

• Metabolic profile.

Mechanistic Studies

Further investigation into:

• Microtubule disruption;

• Autophagy modulation;

• Chemotherapy sensitisation;

• Tumor metabolism.

Safety Studies

Formal pharmacokinetic and toxicity evaluations are needed, particularly for high-dose protocols.

---

Conclusion

When reorganised clinically rather than chronologically, the anecdotal pancreatic cancer reports reveal recurring patterns involving:

• Liver metastasis responses;

• Rapid CA19-9 decline;

• Combination therapy use;

• Delayed-response kinetics;

• Extensive metabolic co-interventions.

The reports remain highly vulnerable to:

• Selection bias;

• Publication bias;

• Survivorship bias;

• Treatment confounding.

Accordingly, the current evidence should be viewed as hypothesis-generating rather than confirmatory.

Nevertheless, the recurring themes may justify prospective registries, translational studies, and controlled pilot investigations.

---

References

1. OneDayMD. Fenbendazole and Ivermectin for Pancreatic Cancer Case Reports. 2026.